Unicycive Therapeutics announced that the U.S. Food and Drug Administration has granted orphan drug designation to UNI-494 for the prevention of Delayed Graft Function in kidney transplant patients. UNI-494 is a cytoprotective agent that elicits an ischemic preconditioning effect by activating KATP channels in mitochondria to restore mitochondrial function. As previously announced, on March 12, 2024, Unicycive will present data on the efficacy of UNI-494 in animal models of DGF and a poster describing the ongoing Phase 1 clinical trial design for UNI-494 in healthy volunteers at the 29th International Conference on Advances in Critical Care Nephrology AKI and CRRT 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on UNCY:
- Unicycive Therapeutics’ prevention of delayed graft function gets orphan status
- Unicycive prevention of delayed graft function treatment granted orphan status
- Unicycive Therapeutics Averts Nasdaq Delisting Concerns
- Unicycive Therapeutics initiated with an Outperform at Noble Capital
- Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting